Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from AbbVie

AbbVie Just Sparked a 46% Rally in Apogee. Here’s Why This $10.9 Billion Deal Could Be a Win for AbbVie Investors.

Apogee’s rally may be over, but AbbVie’s upside from the deal could just be getting started.

Barchart

The $11 Billion Reason Abbvie Stock Is Up Today

AbbVie stock rallied today on the $10.9 billion acquisition of Apogee Therapeutics. Here’s how you should play ABBV shares at current levels.

Barchart

Wall Street ends mixed as investors focus on Iran talks

US stocks have closed mostly lower as investors assess progress in the ‌latest round of negotiations involving the United States and Iran.

AAP

From analysis to the latest developments in health,
read the most diverse news in one place.

US stocks today: S&P 500, Dow tick higher as investors weigh Mideast negotiations

Wall Street's major indexes opened little changed on Monday as investors returned from the long holiday weekend and awaited clarity on US-Iran negotiations,

The Economic Times

Global drugmakers rush to boost US presence as tariff threat looms

Global drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Companies are investing billions in new plants and expanding existing facilities across America. These moves aim to avoid penalties and ensure supply chains remain robust. Several major pharmaceutical firms have…

The Economic Times

Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment

Aldeyra Therapeutics (NASDAQ:ALDX) Chief Executive Todd Brady said the company expects near-term feedback from the U.S. Food and Drug Administration on its dry eye disease candidate reproxalap, following a third complete response letter tied to efficacy questions. Speaking at a Jefferies fireside c

MarketBeat

Life-prolonging drug for advanced ovarian cancer gets go-ahead in England

Elahere is first new drug for chemotherapy-resistant ovarian cancer to be approved by NHS for 20 years

The Guardian - UK

Read news from The Economist, FT, and more,
with one subscription

'Significant breakthrough' as new ovarian cancer treatment approved for NHS use

A former NHS worker from north London who is taking the drug says the new treatment has let her ‘get on with my life’

Evening Standard

Breakthrough ovarian cancer drug that extends lives to be free on NHS for first time

Experts have hailed the ‘landmark’ decision from the National Institute for Health and Care Excellence to approve the treatment for NHS use

The Independent UK

AbbVie Stock: Is ABBV Outperforming the Healthcare Sector?

AbbVie has underperformed the healthcare sector, and analysts remain somewhat optimistic about the stock’s outlook.

Barchart

5 High-Yield Stocks and ETFs to Buy and Hold for the Next Decade

Five high-yield names spanning pharmaceuticals, consumer staples, energy, and ETFs offer income investors compelling yields and durable businesses for a ten-year hold.

MarketBeat

AbbVie Delivers Strong Q1 Earnings Beyond Humira. This Dividend King Still Shines.

Q1 earnings show this Dividend King still looks built for the long term.

Barchart

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the Beat

Big Pharma stalwarts AbbVie, AstraZeneca, and GSK beat Q1 revenue expectations, raising guidance and offering a potential tailwind for the flailing medical sector.

MarketBeat

AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?

AbbVie's early 2026 price pullback is an irresistable opportunity for buy-and-hold investors looking for income and compounding opportunities.

MarketBeat

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Only 3 Dividend Kings Passed This Brutal Screen. They Could Pay You Well for Years to Come.

Three Dividend Kings with 50+ years of raises combine reliable income, solid growth, and analyst support, making them stand out in a shaky market.

MarketBeat

3 Dividend Aristocrats Whose Yields Can Help Combat Inflation

These three Dividend Aristocrats offer yields above 3% and a history of consistent dividend growth, making them strong choices to help stay ahead of inflation.

MarketBeat

3 Companies Aggressively Raising Dividends While Others Play Defense

A strong dividend stock may not only pay a healthy distribution, but also be able to continue to grow its payouts thanks to steady, strong business.

Barchart

What You Need to Know Ahead of AbbVie’s Earnings Release

AbbVie will release its first-quarter earnings this month, and analysts anticipate a double-digit bottom-line growth.

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

These 3 Cash Flow Machines Provide Stability in Uncertain Markets

Three companies with a combination of excellent name recognition within their industries and strong free cash flow potential provide a stable investment option.

MarketBeat

AbbVie’s Prognosis: The February Dip Looks Like a Buy Signal

AbbVie is on track to grow, drive cash flow, and pay a healthy dividend for the long term: institutions and analysts are accumulating this stock.

Barchart

AbbVie Stock: Analyst Estimates & Ratings

After Humira’s patent cliff, what do analysts think about AbbVie’s stock now?

Barchart

The 3 Most Reliable Dividend Stocks to Buy for Years to Come

These three dividend stocks are long-term winners with dependable payouts.

MarketBeat

AbbVie Call Options Spike 2,599%: Tracking the Big Bet

Large institutional investors are positioning for growth as a leading biopharmaceutical firm enters the obesity market and reaches a federal agreement.

MarketBeat

Flu Season's Here—This Dividend-Payer Controls the Shot Market

With flu season in full swing, drugmakers are hoping for a short-term tailwind after a lackluster 2025. Sanofi could be the winning ticket.

Barchart

What to Expect From AbbVie's Next Quarterly Earnings Report

AbbVie will release its fourth-quarter earnings soon, and analysts anticipate a double-digit bottom-line growth.

1 2 3 4 5

People

Donald Trump

197,779 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.